{
  "ticker": "IMM",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02960756",
  "id": "02960756",
  "pages": 2,
  "price_sensitive": true,
  "date": "20250623",
  "time": "0833",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250623/pdf/06kztvb5zpl1k0.pdf",
  "summary": "### Key Material Information:  \n- **Positive Phase I data** for IMP761 shows **significant T cell suppression (80% at 0.9 mg/kg)** and **favourable safety profile**.  \n- **Higher dose escalation planned** (2.5, 7, and 14 mg/kg).  \n- **Next data readout expected H2 CY2025**.  \n- **First-in-class LAG-3 agonist** targeting autoimmune diseases (rheumatoid arthritis, Type 1 diabetes, multiple sclerosis) with multi-billion-dollar market potential.  \n\n*No capital markets actions (e.g., raising, halt) or financial figures disclosed.*",
  "usage": {
    "prompt_tokens": 1798,
    "completion_tokens": 134,
    "total_tokens": 1932,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-22T22:48:46.589083"
}